Navigation Links
Genetic Disorder Drug Helps Reverse Heart Muscle Enlargement
Date:5/30/2008

Mice given BH4 had lower production of toxic free radicals from hypertension, study finds

FRIDAY, May 30 (HealthDay News) -- Tests on mice suggest that the drug BH4 may hold promise as a treatment for people with enlarged hearts, says a Johns Hopkins University study.

Currently, BH4 is used to treat a genetic disorder called phenylketonuria (PKU), a metabolic disorder in which a toxic buildup of a molecule called phenylalanine can cause brain damage.

In this study, the Hopkins team found that BH4 stabilized the pumping function of failing, enlarged hearts in mice and significantly decreased the size of the heart muscle in just over a month.

"Our results show for the first time the pivotal role played by BH4 in stopping and reversing the weakening and damage done -- even in severe cases -- to the heart muscle as a result of hypertension and subsequent hypertrophy [enlargement]," senior investigator Dr. David Kass, a professor at the Johns Hopkins University School of Medicine and its Heart Institute, said in a prepared statement.

"This key evidence may help us develop new therapies that stop and reverse hypertrophy, preventing the disease from leading to end-stage heart failure and keeping affected individuals from needing heart-assist pumps or a treatment of last resort, the heart transplant," Kass said.

In this study, the researchers gave a daily dose of 5 milligrams of BH4 per 25 grams of body weight to 31 mice whose hearts were damaged by hypertension. This group of mice was compared to a group of mice with hypertension-damaged hearts who received a placebo.

After five weeks, the BH4 group showed "remarkable improvements" compared to the placebo group. Ejection-fraction measures of heart pumping function improved from 48 percent at the start of BH4 treatment to 59 percent by the end of the study. In the placebo group, average pumping function decreased from 48 percent to 35 percent.

Heart weight, as measured by muscle mass, decreased from an average of 290 milligrams at the start of BH4 treatment to an average of 209 milligrams by the end of the study. In the placebo group, average heart weight was 330 milligrams by the end of the study.

The BH4 group also showed improvements in other areas, including heart wall thickness, muscle cell size and fibrosis, and lowered production of dangerous free radicals.

The study was published in the May 20 issue of Circulation.

More information

The American Heart Association has more about heart failure.



-- Robert Preidt



SOURCE: Johns Hopkins University, news release, May 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. USC researchers identify genetic markers that predict efficacy of novel cancer drug
2. Common Genetic Variant Tied to Lung Cancer Risk
3. Determining genetic signature of lung tumors can help guide treatment
4. Will lung cancer recur? A genetic test may provide the answer
5. Genetic loci assigned for musical aptitude in Finnish families
6. Geneticists at the American Museum of Natural History trace the evolution of St. Louis encephalitis
7. Genetic links to impaired social behavior in autism
8. Genetic Engineering and Biotechnology News reports on early ADMET use
9. Combined physical and genetic map finds cancers ignition key
10. Research program focuses on genetic mutations and cancer risk
11. Pelosi: Genetic Information Nondiscrimination Act Will Protect Americans from Misuse of Genetic Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten ... so, you may be interested in participating in a research study that focuses on ... to understand more about the relational aspects of adults who have gluten sensitivities who ...
(Date:8/19/2017)... ... August 18, 2017 , ... Western University of Health Sciences will host ... the University’s new Center for Innovation on Wednesday, September 6, 2017. , The symposium ... 1, followed by a technology exhibition from 1 to 3 p.m. showcasing virtual reality ...
(Date:8/19/2017)... ... August 18, 2017 , ... ... Act of 2017, legislation that provides for greater public access to over-the-counter (OTC) ... loss to access OTC hearing aids without being seen by a certified and ...
(Date:8/19/2017)... ... August 19, 2017 , ... Curl Keeper® is excited ... The Curl Leaders, Editors’ Choice 2017 Award for the second year in a row. ... stylists and curlies alike was voted Best Moisturizer for Type 2 Wavies and Best ...
(Date:8/19/2017)... San Diego, CA (PRWEB) , ... August 19, 2017 , ... ... Neo-Nazis, and the KKK by saying there are two sides. There are not two ... merely a way to rationalize violence and prejudice, and the NPEIV stands against all ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
(Date:7/31/2017)... 31, 2017 Three Tru-D SmartUVC robots have arrived ... Korea . Tru-D, short for "Total Room Ultraviolet Disinfection," is a ... an environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs ... "Although the BAACH has a very ...
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
Breaking Medicine Technology: